Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024Business Wire • 09/13/24
Repare: Q4 2024 Is A Major Inflection Point With Lunresertib, Camonsertib DataSeeking Alpha • 08/30/24
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical PortfolioBusiness Wire • 08/28/24
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue EstimatesZacks Investment Research • 08/06/24
Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial ResultsBusiness Wire • 08/06/24
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRIBusiness Wire • 06/26/24
Foundation Medicine Announces Partnership with Repare Therapeutics to Provide Genomic Profiling Services to Support Clinical Trials and to Develop Companion Diagnostic for LunresertibBusiness Wire • 06/12/24
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical TrialBusiness Wire • 06/10/24
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian CancerBusiness Wire • 06/04/24
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceBusiness Wire • 06/03/24
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024Business Wire • 05/29/24
Repare Therapeutics Provides Business and Clinical Update and Reports First Quarter 2024 Financial ResultsBusiness Wire • 05/07/24
Repare Therapeutics & Debiopharm Announce First Patient Dosed in Phase 1/1b MYTHIC Trial Evaluating the Synthetic Lethal Combination of PKMYT1 and WEE1 InhibitionBusiness Wire • 04/30/24
Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1b Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1 AND PKMYT1 InhibitionBusiness Wire • 04/30/24
Repare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsBusiness Wire • 03/21/24
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTXPRNewsWire • 03/12/24
Repare Therapeutics Inc. Investigation Ongoing: Contact Levi & Korsinsky to Discuss Your Rights - RPTXAccesswire • 03/05/24
ATTENTION Repare Therapeutics Inc. Investors: You May Have Been Affected by Fraud- Contact Levi & Korsinsky to Discuss Your RightsAccesswire • 02/28/24
Repare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsBusiness Wire • 02/28/24
Repare Therapeutics Inc. Investigation Ongoing: Contact Levi & Korsinsky About Potential Securities Fraud Allegations - RPTXAccesswire • 02/27/24
Repare Therapeutics Inc. (RPTX) May Report Negative Earnings: Know the Trend Ahead of Q4 ReleaseZacks Investment Research • 02/20/24
Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)Business Wire • 02/16/24